BDAZ - As you said slide 17 was the money shot for most of your questions.

1. I don't know how current that 200 events # is. Could be as much as 5 weeks old now. That was the time difference between the slides and the presentation at the Zenith meeting. 

2. No indication of providing an update of event numbers prior to achieving the total.

3. Q1

4. As per slide 6, this is an Adaptive Trial

5. Time line changes for other trials, Slide 5

6. US patients, none enrolled, not needed, they only needed to match the ethnic makeup of the US which is already achieved with the trial design. The FDA has agreed to this. This saved the company a lot of money.

7. Top line data. They will try to give guidance on the sub studies. Depends on the data collection process.

More later

tada